Assessing the use habits and efficacy of intracavernosal alprostadil: is it tolerable and sustainable?
DOI:
https://doi.org/10.18203/2349-2902.isj20240749Keywords:
Alprostadil, Erectile dysfunction, Intracavernosal treatment, Sexual functionAbstract
Background: The aim of this study was to evaluate the efficacy of intracavernosal alprostadil treatment for erectile dysfunction and the evaluation of factors such as ease of drug use, duration of use, and difficulties in habituation.
Methods: The data of 40 patients who were treated for erectile dysfunction, had inadequate response from first-line treatment modalities, received intracavernosal alprostadil in second-line treatment and continued treatment for more than 12 weeks without interruption were analyzed. Sexual function status was evaluated by 15-question international ındex of erectile function (IIEF-15) form and degree of erection (1-10 points). In addition, duration of use, self-administered dose, reasons for difficulty, and reasons for treatment interruption were investigated.
Results: The mean duration of use was 21.38 months. Patients switched to self-administration after an average minimum dose of 2.23 doses. After 12 weeks, 50% of the patients discontinued self-administration, 10% because of difficulty in administration, 55% because of inadequate erection response, 25% because of time, and 10% because of additional health problems. IIEF-15 parameters and the degree of erection were found to improve significantly after administration (p<0.05 for all parameters).
Conclusions: Intracavernosal alprostadil provides significant improvement in sexual function, but since it is an invasive application, patients have difficulty in getting used to it, self-administration is started after a minimum of 2 doses, and the reason for discontinuation is mostly due to inadequate erectile response.
References
Irwin GM. Erectile Dysfunction. Prim Care. 2019;46(2):249-55.
Yurdakul T, Karabacakoğlu T, Karaköse S, Özeroğlu M. The Comparison of Penile Color Doppler Ultrasonography and Pharmacocavernometry in the Diagnosis of Venous Impotences. Selcuk Med J. 2000;16(1):27-33.
Haliloğlu AH, Gülpınar Ö. Intracavernosal Procedures in the Medical Treatment of Erectile Dysfunction. Turk Urol Sem. 2010;1:80-4.
Küçük MF, Ayan A, Çetin SY, Erol MK. The Relationship between Erectile Dysfunction and Macular and Radial Peripapillary Microvasculer Densities in Behçet's Patients without Ocular Involvement. Selcuk Med J. 2022;38(1):8-16.
Cumhur T, Karakose S, Sert IU, Olcer T. Effectiveness of PTA or intravascular stents in the treatment of the patients with aortoiliac occlusion or stenosis and empotance. Selcuk Med J. 1994;10(1):1-6.
Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, et al. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. J Sex Med. 2023;21(1):29-32.
Cenik A. Prostanoidlerin Kan Basıncı Regülasyonundaki Rolü. Selcuk Med J. 1989;5(3):180-2.
Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15(3):421-8.
Vieillard V, Eychenne N, Astier A, Yiou R, Deffaux C, Paul M. Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction. Ann Pharm Fr. 2013;71(5):358-63.
Serel TA, Öztürk A, Koşar A, Tahoğlu M. Semirijid Penil Protez Uygulanan 15 Hastanın Değerlendirilmesi. Selcuk Med J. 1997;13(4):251-4.
Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, et al. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. J Sex Med. 2023;21(1):29-32.
Hew MR, Gerriets V. Prostaglandin E1. Treasure Island (FL): StatPearls Publishing. 2023.
Anaissie J, Hellstrom WJG. Clinical use of alprostadil topical cream in patients with erectile dysfunction: A review. Res Reports Urol. 2016;8:123-31.
Hamzehnejadi M, Tavakoli MR, Homayouni F, Jahani Z, Rezaei M, Langarizadeh MA, et al. Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. Sex Med Rev. 2022;10(4):764-81.
Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its pharmacodynamic andpharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging. 1996;8(1):56-74.
Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873-7.
Godschalk MF, Chen J, Katz PG, Mulligan T. Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol. 1994;151(6):1530-2.
El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res. 2006;18(2):180-5.
Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol. 1991;146(3):786-9.
Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15(3):421-8.
Taşkapu HH, Sönmez MG, Kılınç MT, Altınkaya N, Aydın A, Balasar M. Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism. Andrologia. 2020;52(10):e13759.
Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, Romero J. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int J Impot Res. 2018;30(5):203-8.
